Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | FGFR2 C491A FGFR2 V564L |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| FGFR2 C491A FGFR2 V564L | Advanced Solid Tumor | resistant | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 C491A and FGFR2 V564L were resistant to Lytgobi (futibatinib) in culture (PMID: 42010121). | 42010121 | |
| FGFR2 C491A FGFR2 V564L | Advanced Solid Tumor | resistant | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 C491A and FGFR2 V564L were resistant to Pemazyre (pemigatinib) in culture (PMID: 42010121). | 42010121 | |
| FGFR2 C491A FGFR2 V564L | Advanced Solid Tumor | resistant | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 C491A and FGFR2 V564L were resistant to Truseltiq (infigratinib) in culture (PMID: 42010121). | 42010121 | |
| FGFR2 C491A FGFR2 V564L | Advanced Solid Tumor | predicted - sensitive | Pralsetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gavreto (pralsetinib) decreased phosphorylation of Fgfr, Akt and S6rp, and inhibited viability in cells expressing FGFR2 C491A and FGFR2 V564L in culture (PMID: 42010121). | 42010121 | |
| FGFR2 C491A FGFR2 V564L | Advanced Solid Tumor | sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Balversa (erdafitinib) decreased phosphorylation of Fgfr, Akt and S6rp, and inhibited viability in cells expressing FGFR2 C491A and FGFR2 V564L in culture (PMID: 42010121). | 42010121 |